NCT02661503View on ClinicalTrials.gov

HD21 for Advanced Stages

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

1,500

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

September 30, 2025

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG

Bleomycin

DRUG

Etoposide

DRUG

Doxorubicin

DRUG

Cyclophosphamide

DRUG

Vincristine

DRUG

Procarbazine

DRUG

Prednisone

DRUG

Brentuximab Vedotin

DRUG

Dacarbazine

DRUG

Dexamethasone

Trial Locations (1)

Unknown

University Hospital of Cologne, Cologne

All Listed Sponsors

lead

University of Cologne

OTHER